Medical therapy is critical in preventing the worst complications of peripheral artery disease (PAD), among them heart attack ...

In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs ...

Beta-blocker use did not result in a lower incidence of composite death or new AMI, all-cause death, AMI, or heart failure ...

The TOPSPIN trial showed that three different antihypertensive regimens result in similar control of blood pressure. Patients with hypertension were randomized to starting doses of amlodipine plus ...

Three dual combinations of hypertension medications in one polypill – amlodipine and perindopril; perindopril and indapamide; or amlodipine and indapamide – were equally effective in reducing blood ...

Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic ...

The BRAIN-AF trial failed to show that rivaroxaban prevents cognitive decline, stroke, or TIA among patients with AF. The primary outcome, cognitive decline (defined by a ≥2-point reduction in ...

The MHYH trial showed that in patients in low- and middle-income countries requiring permanent pacemaker implantation, reconditioned devices may provide a noninferior, more affordable alternative to ...

Intravenous infusion of exenatide, a GLP-1 analog medication, during heart surgeries involving bypass did not significantly reduce the risk of death, stroke or organ failure, according to results from ...

New findings from CLEAR SYNERGY (OASIS 9) comparing spironolactone vs. placebo in patients with myocardial infarction (MI) found that the mineralocorticoid receptor antagonist did not reduce the ...

Do electronic "nudges" or decision-support systems impact patient and clinician decision-making? Two separate studies presented at AHA 2024 explore answers to this question, specifically in the areas ...

Rivaroxaban did not reduce the incidence of cognitive decline, stroke or transient ischemic attack (TIA) in patients younger than 65 with nonvalvular atrial fibrillation (AFib) and low risk for stroke ...